53 related articles for article (PubMed ID: 1301675)
1. [Cisplatin ototoxicity: the experience of the Institute of Oncology in Bari].
Grammatica L; Achille G; Cortese M; Casaula M; Mininni F
Acta Otorhinolaryngol Ital; 1992; 12(4):383-8. PubMed ID: 1301675
[TBL] [Abstract][Full Text] [Related]
2. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
3. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
7. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
8. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
10. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
11. [Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Beck A; Maurer J; Welkoborsky HJ; Mann W
HNO; 1992 Apr; 40(4):123-7. PubMed ID: 1601678
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of cis-diamminedichloroplatinum (II) in the multidisciplinary treatment of head and neck cancers].
Yajin K; Harada Y; Nakata M; Takebayashi S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1737-43. PubMed ID: 3729479
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
[TBL] [Abstract][Full Text] [Related]
15. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
16. [The ototoxicity of cisplatin: a clinical study].
Vantrappen G; Rector E; Debruyne F
Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
[TBL] [Abstract][Full Text] [Related]
17. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
18. Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose.
Timmer FC; Hanssens PE; van Haren AE; Mulder JJ; Cremers CW; Beynon AJ; van Overbeeke JJ; Graamans K
Laryngoscope; 2009 Jun; 119(6):1076-81. PubMed ID: 19399836
[TBL] [Abstract][Full Text] [Related]
19. High-dose cisplatin treatment: hearing loss and plasma concentrations.
Laurell G; Jungnelius U
Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
[TBL] [Abstract][Full Text] [Related]
20. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial.
Kumar S; Pandey M; Lal P; Rastogi N; Maria Das KJ; Dimri K
Radiother Oncol; 2005 May; 75(2):186-92. PubMed ID: 16086908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
